

12

In re Application of: Yoseph SHAALTIEL et al.  
Serial No.: 10/554,387  
Filed: October 25, 2005  
Restriction Office Action Mailing Date: April 7, 2008

Examiner: Delia M. RAMIREZ  
Group Art Unit: 1652  
Attorney Docket: 30570

**REMARKS**

Applicants acknowledge withdrawal of the Restriction of January 9, 2008.

In the Restriction Action of April 7, 2008, the Examiner has alleged that claims 73-141 lack a unifying special technical feature in view of Martin et al. and Garger et al., and as such are subject to restriction to single invention from inventions indicated in Groups I-VI, as defined by the Examiner.

Applicants elect Group III, claims 99-102, 104-120 and 122-128, drawn to a glucocerebrosidase and compositions thereof. All of claims 99-102, 104-120 and 122-128 are encompassed by the elected invention.

Where the compositions and pharmaceutical compositions of elected claims of Group III will be found novel and non-obvious, Applicants reserve the right to request rejoinder of non-elected claims drawn on processes of manufacture and methods of use depending from or otherwise including all the limitations of the allowed composition claims.

In addition, Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to the non-elected Inventions.

Further, new claims 142-144 have been added herewith. No new material has been introduced.

Respectfully submitted,



Martin D. Moynihan  
Registration No. 40,338

Date: May 7, 2008